A single missense mutant of Smad3 inhibits activation of both Smad2 and Smad3, and has a dominant negative effect on TGF‐β signals

[1]  Yigong Shi,et al.  The L3 loop: a structural motif determining specific interactions between SMAD proteins and TGF‐β receptors , 1998, The EMBO journal.

[2]  Y. Yuasa,et al.  Genomic structure of the human Smad3 gene and its infrequent alterations in colorectal cancers. , 1998, Cancer letters.

[3]  Kohei Miyazono,et al.  TGF-β signalling from cell membrane to nucleus through SMAD proteins , 1997, Nature.

[4]  Xiao-Fan Wang,et al.  Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein , 1997, Molecular and cellular biology.

[5]  J. Massagué,et al.  Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. , 1997, Genes & development.

[6]  C. Wernstedt,et al.  Phosphorylation of Ser465 and Ser467 in the C Terminus of Smad2 Mediates Interaction with Smad4 and Is Required for Transforming Growth Factor-β Signaling* , 1997, The Journal of Biological Chemistry.

[7]  Jeffrey L. Wrana,et al.  TβRI Phosphorylation of Smad2 on Ser465 and Ser467 Is Required for Smad2-Smad4 Complex Formation and Signaling* , 1997, The Journal of Biological Chemistry.

[8]  C. Heldin,et al.  Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling , 1997, Nature.

[9]  K. Miyazono,et al.  Smad6 inhibits signalling by the TGF-β superfamily , 1997, Nature.

[10]  R. Weinberg,et al.  Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Takeshi Imamura,et al.  TGF‐β receptor‐mediated signalling through Smad2, Smad3 and Smad4 , 1997 .

[12]  Yigong Shi,et al.  A structural basis for mutational inactivation of the tumour suppressor Smad4 , 1997, Nature.

[13]  K. Kinzler,et al.  Frequency of Smad gene mutations in human cancers. , 1997, Cancer research.

[14]  J. Wrana,et al.  The MAD-Related Protein Smad7 Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signaling , 1997, Cell.

[15]  A. Roberts,et al.  Characterization of Functional Domains within Smad4/DPC4* , 1997, The Journal of Biological Chemistry.

[16]  A. Hata,et al.  TGF-β signalling through the Smad pathway , 1997 .

[17]  R. Derynck,et al.  Heteromeric and homomeric interactions correlate with signaling activity and functional cooperativity of Smad3 and Smad4/DPC4 , 1997, Molecular and cellular biology.

[18]  P. Dijke,et al.  DPC4 (SMAD4) mediates transforming growth factor-β1 (TGF-β1) induced growth inhibition and transcriptional response in breast tumour cells , 1997, Oncogene.

[19]  C. Heldin,et al.  Identification of Smad2, a Human Mad-related Protein in the Transforming Growth Factor β Signaling Pathway* , 1997, The Journal of Biological Chemistry.

[20]  P. Hoodless,et al.  MADR2 Is a Substrate of the TGFβ Receptor and Its Phosphorylation Is Required for Nuclear Accumulation and Signaling , 1996, Cell.

[21]  Y. Takagi,et al.  Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. , 1996, Gastroenterology.

[22]  J. Massagué,et al.  Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways , 1996, Nature.

[23]  R. Derynck,et al.  Receptor-associated Mad homologues synergize as effectors of the TGF-β response , 1996, Nature.

[24]  Irene L Andrulis,et al.  MADR2 Maps to 18q21 and Encodes a TGFβ–Regulated MAD–Related Protein That Is Functionally Mutated in Colorectal Carcinoma , 1996, Cell.

[25]  Scott E. Kern,et al.  Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers , 1996, Nature Genetics.

[26]  T. Mitsudomi,et al.  Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. , 1996, Cancer research.

[27]  Anita B. Roberts,et al.  Tumor suppressor activity of the TGF-β pathway in human cancers , 1996 .

[28]  Kathleen R. Cho,et al.  DPC4 gene in various tumor types. , 1996, Cancer research.

[29]  R. Lotan,et al.  DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. , 1996, Cancer research.

[30]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[31]  Luzhe Sun,et al.  Demonstration That Mutation of the Type II Transforming Growth Factor β Receptor Inactivates Its Tumor Suppressor Activity in Replication Error-positive Colon Carcinoma Cells (*) , 1995, The Journal of Biological Chemistry.

[32]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[33]  K. Miyazono,et al.  A Human Keratinocyte Cell Line Produces Two Autocrine Growth Inhibitors, Transforming Growth Factor-β and Insulin-like Growth Factor Binding Protein-6, in a Calcium- and Cell Density-dependent Manner (*) , 1995, The Journal of Biological Chemistry.

[34]  M. Sporn,et al.  Physiological Actions and Clinical Applications of Transforming Growth Factor-β (TGF-β) , 1993 .